Product Description
Cinnarizine is an antihistamine that stops you feeling or being sick (nausea or vomiting). It's known as a drowsy (sedating) antihistamine. It's more likely to make you feel sleepy than other antihistamines. It's used for: travel sickness (also called motion sickness) (Sourced from: https://www.nhs.uk/medicines/cinnarizine/)
Mechanisms of Action: H1 Antagonist,Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Chulalongkorn University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Motion Sickness
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Cinnarizine Study | P4 |
Completed |
Motion Sickness |
2009-04-30 |
|
| 2012-004002-10 | N/A |
Active, not recruiting |
Urticaria |
None |